Literature DB >> 28217897

Captopril apparently increase and cisplatin apparently decrease human albumin concentration in artificial urinary solutions.

Rafał Kuzioła1, Barbara Marczewska1, Krzysztof Marczewski2.   

Abstract

BACKGROUND: Measurement of urinary albumin (HSA) is very important in diagnostic of kidney diseases. Much less is known about the possible impact of substances present in urine together with albumin on the results of measurements.
METHODS: We investigated the effect of the presence of captopril and cisplatin in the solution on the result of the determination of HSA by native polyacrylamide gel electrophoresis. Protein conformation in the absence and presence of the drugs was examined using Fourier Transform Infrared Spectroscopy (FTIR).
RESULTS: The presence of captopril apparently increases HSA concentration while cisplatin causes an apparent decrease in the HSA concentration. The presence of both drugs also influence the secondary structure forms of HSA albumin investigated by FTIR.
CONCLUSION: Both drugs tested in the concentration of human use can have an impact on the results of determination of albumin in urine which can influence clinical decision.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  drugs interference; native polyacrylamide gel electrophoresis; urine albumin determination

Mesh:

Substances:

Year:  2017        PMID: 28217897      PMCID: PMC6817197          DOI: 10.1002/jcla.22127

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  8 in total

1.  Cisplatin binding to human serum albumin: a structural study.

Authors:  Giarita Ferraro; Lara Massai; Luigi Messori; Antonello Merlino
Journal:  Chem Commun (Camb)       Date:  2015-06-11       Impact factor: 6.222

2.  Methodological evaluation and comparison of five urinary albumin measurements.

Authors:  Rui Liu; Gang Li; Xiao-Fan Cui; Dong-Ling Zhang; Qing-Hong Yang; Xiao-Yan Mu; Wen-Jie Pan
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

3.  Nephroprotection in diabetes mellitus.

Authors:  N K Singh
Journal:  Clin Exp Hypertens       Date:  1999 Jan-Feb       Impact factor: 1.749

Review 4.  An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.

Authors:  George J Dugbartey; Luke J Peppone; Inge A M de Graaf
Journal:  Toxicology       Date:  2016-10-04       Impact factor: 4.221

5.  Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats.

Authors:  J Hrenák; K Arendášová; R Rajkovičová; S Aziriová; K Repová; K Krajčírovičová; P Celec; N Kamodyová; A Bárta; M Adamcová; L Paulis; F Simko
Journal:  Physiol Res       Date:  2013       Impact factor: 1.881

6.  Cisplatin binding sites on human albumin.

Authors:  A I Ivanov; J Christodoulou; J A Parkinson; K J Barnham; A Tucker; J Woodrow; P J Sadler
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

7.  Effect of ethanol or/and captopril on the secondary structure of human serum albumin before and after protein binding.

Authors:  Shan-Yang Lin; Yen-Shan Wei; Mei-Jane Li; Shun-Li Wang
Journal:  Eur J Pharm Biopharm       Date:  2004-05       Impact factor: 5.571

8.  The interaction of human serum albumin with selected lanthanide and actinide ions: Binding affinities, protein unfolding and conformational changes.

Authors:  Manjoor Ali; Amit Kumar; Mukesh Kumar; Badri N Pandey
Journal:  Biochimie       Date:  2016-01-25       Impact factor: 4.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.